Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil

Expert Review of Clinical Pharmacology

Volumn 9, Issue 7, 2016, Pages 991-999

  Gomes, Rosângela Maria ^a   Guerra Júnior, Augusto Afonso ^a   de Lemos, Lívia Lovato Pires ^a   Costa, Juliana de Oliveira ^a   Almeida, Alessandra Maciel ^a   Alvares, Juliana ^a   Filho, Charles Simão ^a   Cherchiglia, Mariângela Leal ^a   Andrade, Eli Iola Gurgel ^a   Godman, Brian ^b,c   Acurcio, Francisco Assis ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Brazil; Cyclosporine; Graft survival; Immunosuppressants; Kidney transplantation; Survival rates; Tacrolimus

Indexed keywords

CYCLOSPORIN; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE; AGED; ARTICLE; BRAZIL; CADAVER KIDNEY; CHRONIC KIDNEY DISEASE; DIABETIC NEUROPATHY; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; RENAL GRAFT DYSFUNCTION; RENAL REPLACEMENT THERAPY; TREATMENT DURATION; ADOLESCENT; COMPARATIVE STUDY; DRUG EFFECTS; HEMODIALYSIS; KAPLAN MEIER METHOD; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BRAZIL; CYCLOSPORINE; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; TIME FACTORS; YOUNG ADULT;

EID: 84976586785     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1080/17512433.2016.1190270     Document Type: Article

References (45)

1. A.Levin, P.E.Stevens, R.W.Bilous Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1.
2. R.C.Sesso, A.A.Lopes, F.S.Thomé, et al. Brazilian Chronic Dialysis Survey 2013 – trend analysis between 2011 and 2013. J Bras Nefrol. 2014;36(4):476.
3. J.E.Romão Junior. Doença renal crônica: definição epidemiologia e classificação. J Bras Nefrol. 2004;26(3, suppl. 1):1.
4. G.Opelz, B.Döhler. Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation. 2007;84(2):137–143.
5. G.Machnicki, L.Seriai, M.A.Schnitzler. Economics of transplantation: a review of the literature. Transplant Rev. 2006;20(2):61–75.
6. J.Álvares, C.C.Cesar, F.A.Acurcio, et al. Quality of life of patients in renal replacement therapy in Brazil: comparison of treatment modalities. Qual Life Res. 2012;21(6):983–991.
7. S.Hariharan, C.P.Johnson, B.A.Bresnahan, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342(9):605–612.
8. F.K.Port, D.M.Dykstra, R.M.Merion, et al. Trends and results for organ donation and transplantation in the United States, 2004. Am J Transplant. 2005;5(4p2):843–849.
9. M.P.Gómez, B.Pérez, M.Manyalich International registry in organ donation and transplantation – 2013. Transplant Proc. 2014;46(4):1044–1048.
10. J.O.Medina-Pestana, M.L.Vaz, S.I.Park, et al. Organ transplantation in Brazil in the year 2002. Transplant Proc. 2004;36(4):799–801.
11. BRASIL. Portaria SAS/MS nº 221 de 01 de abril de 2002 da Secretaria de Atenção à Saúde do Ministério da Saúde. Aprova a Diretrizes Clínicas e Protocolos Terapêuticos de Medicamentos Excepcionais e de Alto Custo no SUS. Transplantes Renais. In: Saúde Md, ed. Diário Oficial da União Republica Federativa do Brasil, Imprensa Nacional Brasília - DF. Nº 62 - DOU - 2/4/2002. [cited 2015 Oct 2]. http://189.28.128.100/portal_transplante/legislacaosnt/portaria_SAS_n_221_de_01_de_abril_de_2002.pdf
12. BRASIL. Portaria SAS/MS nº 666, de 17 de julho de 2012 da Secretaria de Atenção à Saúde do Ministério da Saúde. Aprova a Diretrizes Clínicas e Protocolos Terapêuticos de Medicamentos Excepcionais e de Alto Custo no SUS. Transplantes Renais [Internet]. In: Saúde Md, ed. Diário Oficial da União, República Federativa do Brasil Imprensa Nacional Brasília - DF.Nº 140 - DOU - 20/07/12 - seção 1 - p.69 2012. ftp://ftp.saude.sp.gov.br/ftpsessp/bibliote/informe_eletronico/2012/iels.jul.12/Iels136/U_PT-MS-SAS-666_170712.pdf
13. J.O.Medina-Pestana, N.Z.Galante, H.Tedesco-Silva Jr., et al. Kidney transplantation in Brazil and its geographic disparity. J Bras Nefrol. 2011;33(4):472–484.
14. S.C.Garcia, L.Lopes, K.L.Schott, et al.Ciclosporina A e tacrolimus: uma revisão. Jornal Brasileiro de Patologia E Medicina Laboratorial. 2004;40(6):393–401.
15. J.Y.Liu, R.X.You, M.Guo, et al. Tacrolimus versus cyclosporine as primary immunosuppressant after renal transplantation: a meta-analysis and economics evaluation. Am J Ther. 2016;23(3):e810–e824.• Good recently published systematic review concerning the efficacy of the different Calcineurin inhibitors.
16. J.R.Azzi, M.H.Sayegh, S.G.Mallat. Calcineurin inhibitors: 40 years later, can’t live without. J Immunol. 2013;191(12):5785–5791.
17. C.C.Almeida, M.R.Silveira, V.E.de Araújo, et al. Safety of immunosuppressive drugs used as maintenance therapy in kidney transplantation: a systematic review and meta-analysis. Pharmaceuticals (Basel). 2013;6(10):1170–1194.
18. A.C.Webster, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ. 2005;331(7520):810.
19. Z.M.El-Zoghby, M.D.Stegall, D.J.Lager, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9(3):527–535.
20. J.D.Pirsch, J.Miller, M.H.Deierhoi, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation. 1997;63(7):977–983.
21. H.U.Meier-Kriesche, J.D.Schold, T.R.Srinivas, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4(3):378–383.
22. A.A.Guerra, C.C.Cesar, M.L.Cherchiglia, et al. Cyclosporine versus tacrolimus in immunosuppressive maintenance regimens in renal transplants in Brazil: survival analysis from 2000 to 2004. Ann Pharmacother. 2010;44(1):192–201.•• Good paper discussing survival analysis with the different calcineurin inhibitors among Brazilian kidney transplant patients.
23. A.A.Guerra Júnior, G.D.Silva, E.I.Andrade, et al. Cyclosporine versus tacrolimus: cost-effectiveness analysis for renal transplantation in Brazil. Rev Saude Publica. 2015;49:1–9.• Recently published paper evaluating the cost-effectiveness of different immunosuppressives for renal transplant patients.
24. C.M.Coeli, K.CamargoJr. Avaliação de diferentes estratégias de blocagem no relacionamento probabilístico de registros. Rev Bras Epidemiol. 2002;5(2):185–196.
25. M.L.Cherchiglia, A.A.Guerra Júnior, E.I.G.Andrade, et al. A construção da base de dados nacional em terapia renal substitutiva (TRS) centrada no indivíduo: aplicação do método de linkage determinístico-probabilístico. Revista Brasileira de Estudos de População. 2007;24(1):163.•• Good paper discussing the application of the deterministic-probabilistic linkage method.
26. A.A.Guerra Junior, F.A.Acúrcio, E.I.Andrade, et al. Ciclosporina versus tacrolimus no transplante renal no Brasil: uma comparação de custos. Cadernos de Saúde Pública. 2010;26(1):163–174.
27. F.A.Acúrcio, C.M.R.Brandão, A.A.Guerra Júnior, et al. Perfil demográfico e epidemiológico dos usuários de medicamentos de alto custo no Sistema Único de Saúde; Perfil demográfico y epidemiológico de los usuarios de medicamentos de costo elevado en el Sistema Único de Salud. Rev Bras Estud Popul. 2009;26(2):263–282.
28. H.Soylu, M.Oruc, O.K.Demirkol, et al. Survival of renal transplant patients: data from a tertiary care center in Turkey. Transplant Proc. 2015;47(2):348–353.
29. K.M.Harada, E.L.Mandia-Sampaio, T.V.de Sandes-Freitas, et al. Risk factors associated with graft loss and patient survival after kidney transplantation. Transplant Proc. 2009;41(9):3667–3670.
30. International Diabetes Federation. 2009. IDF diabetes atlas. 4th ed. Brussels (Belgium): International Diabetes Federation. http://www.idf.org/media/press-materials/diabetes-data
31. M.L.Cherchiglia, E.L.Machado, D.A.C.Szuster, et al. Perfil epidemiológico dos pacientes em terapia renal substitutiva no Brasil, 2000–2004. Ver Saúde Pública. 2010;44(4):639–649.
32. F.G.Cosio, L.J.Hickson, M.D.Griffin, et al. Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transplant. 2008;8(3):593–599.
33. P.D.Chen, M.K.Tsai, C.Y.Lee, et al. Gender differences in renal transplant graft survival. J Formos Med Assoc. 2013;112(12):783–788.
34. J.Y.Zhou, J.Cheng, H.F.Huang, et al. The effect of donor-recipient gender mismatch on short- and long-term graft survival in kidney transplantation: a systematic review and meta-analysis. Clin Transplant. 2013;27(5):764–771.
35. C.Traynor, A.Jenkinson, Y.Williams, et al. Twenty-year survivors of kidney transplantation. Am J Transplant. 2012;12(12):3289–3295.
36. E.V.A.Santiago, M.R.Silveira, V.E.Araújo, et al. Gender in the allocation of organs in kidney transplants: meta-analysis. Rev Saúde Pública. 2015;49:68. [Epub ahead of print]
37. E.L.Machado, M.L.Cherchiglia, F.Acúrcio. [Profile and clinical outcome of patients in waiting list for kidney transplantation, Belo Horizonte (MG, Brazil), 2000–2005]. Cien Saude Colet. 2011;16(3):2373–2382.
38. S.Hariharan, M.A.McBride, W.S.Cherikh, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int. 2002;62(1):311–318.
39. I.D.Kostakis, Moris DN, Barlas A, et al. Impact of donor and recipient age difference on long-term allograft survival after living donor renal transplantation: analysis of 478 cases. Clin Transplant. 2013;27(6):838–843.
40. J.R.Rodelo, J.F.Nieto-Ríos, L.M.Serna-Higuita, et al. Survival of renal transplantation patients older than 60 years: a single-center experience. Transplant Proc. 2013;45(4):1402–1409.
41. J.S.Gill, M.Tonelli, N.Johnson, et al. The impact of waiting time and comorbid conditions on the survival benefit of kidney transplantation. Kidney Int. 2005;68(5):1161–1170.
42. S.Bunnapradist, A.Daswani, S.K.Takemoto. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids. Transplantation. 2003;76(1):10–15.•• Good paper comparing the effectiveness of different calcineurin inhibitors in the United States.
43. G.Opelz, B.Döhler, C.T.Study. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation. 2009;87(6):795–802.•• Good paper discussing the influence of different immunosuppressive regimens among a large number of patients across Europe, North America and Australia/New Zealand.
44. B.Kaplan, J.D.Schold, H.U.Meier-Kriesche. Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol. 2003;14(11):S290–6.• Good paper using a paired kidney analysis to evaluate five-years graft survival among different calcineurin inhibitors.
45. S.Alghamdi, Z.Nabi, E.Skolnik, et al. Cyclosporine versus tacrolimus maintenance therapy in renal transplant. Exp Clin Transplant. 2011;9(3):170.